DeepMed Research

UCB PHARMA SA

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Public, Subsidiary

Established: 1928-01-01

Employees: 9K

Market Cap: $34.9B

Website: https://www.ucb-iberia.com/home

Clinical Trials

A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: Certolizumab Pegol (CZP)

First Posted Date: 2010-12-07

Last Posted Date: 2018-07-31

Lead Sponsor: UCB Pharma

Target Recruit Count: 736

Registration Number: NCT01255761

Locations: 🇺🇸
241, Jonesboro, Arkansas, United States
🇺🇸
103, Fullerton, California, United States
🇺🇸
203, Loma Linda, California, United States

and more 107 locations

Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: CDP6038
Biological: Tocilizumab (Actemra or RoActemra)
Other: Placebo sc
Other: Placebo iv

First Posted Date: 2010-11-17

Last Posted Date: 2024-07-17

Lead Sponsor: UCB Pharma

Target Recruit Count: 221

Registration Number: NCT01242488

Locations: 🇺🇸
132, Houston, Texas, United States
🇺🇸
181, Houston, Texas, United States
🇺🇸
158, San Diego, California, United States

and more 79 locations

Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older

Completed

Conditions: Seizures

Interventions: Drug: Lacosamide

First Posted Date: 2010-11-07

Last Posted Date: 2013-08-08

Lead Sponsor: UCB Pharma

Target Recruit Count: 192

Registration Number: NCT01236001

Trial to Assess Optimized Dosage of Lacosamide as add-on Therapy in Patients With Partial Onset Seizure

Phase 4

Completed

Conditions: Partial Epilepsies

Interventions: Drug: Lacosamide

First Posted Date: 2010-11-05

Last Posted Date: 2018-05-21

Lead Sponsor: UCB Pharma

Target Recruit Count: 100

Registration Number: NCT01235403

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: Placebo
Biological: Certolizumab Pegol (CZP) 200 mg
Biological: Certolizumab Pegol (CZP) 400 mg

First Posted Date: 2010-11-05

Last Posted Date: 2014-03-12

Lead Sponsor: UCB Pharma

Target Recruit Count: 41

Registration Number: NCT01235598

Locations: 🇵🇱
018, Warszawa, Poland
🇩🇰
003, Frederiksberg, Denmark
🇩🇰
002, Hellerup, Denmark

and more 7 locations

Observational Study in Infants Who Are Prescribed Treatment With Keppra® (Levetiracetam) Oral Solution

Completed

Conditions: Epilepsy

First Posted Date: 2010-09-28

Last Posted Date: 2014-11-19

Lead Sponsor: UCB Pharma

Target Recruit Count: 101

Registration Number: NCT01210690

Locations: 🇵🇱
065, Gdansk, Poland
🇮🇹
032, Milano, Italy
🇩🇪
027, Berlin, Germany

and more 24 locations

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: certolizumab pegol

First Posted Date: 2010-08-27

Last Posted Date: 2020-12-17

Lead Sponsor: UCB Pharma

Target Recruit Count: 16

Registration Number: NCT01190410

Locations: 🇺🇸
126, Morristown, New Jersey, United States
🇺🇸
104, Baltimore, Maryland, United States
🇺🇸
114, Orange, California, United States

and more 7 locations

Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise

Completed

Conditions: Idiopathic Restless Legs Syndrome

Interventions: Drug: Neupro®

First Posted Date: 2010-04-30

Last Posted Date: 2012-09-28

Lead Sponsor: UCB Pharma

Target Recruit Count: 687

Registration Number: NCT01113710

Named Patient Program With Rotigotine Transdermal System

Completed

Conditions: Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine

Interventions: Drug: Rotigotine patch

First Posted Date: 2010-03-30

Last Posted Date: 2014-10-20

Lead Sponsor: UCB Pharma

Target Recruit Count: 520

Registration Number: NCT01095484

Locations: 🇺🇸
036, Berkeley, California, United States
🇺🇸
046, Houston, Texas, United States
🇺🇸
085, Fairhope, Alabama, United States

and more 48 locations

National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia® or Disease-modifying Antirheumatic Drugs (DMARDs)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-03-30

Last Posted Date: 2020-07-16

Lead Sponsor: UCB Pharma

Target Recruit Count: 12500

Registration Number: NCT01095393

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy